This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 23 from Patent US 20120328692
General Information
DRACP ID DRACP01448
Peptide Name Sequence 23 from Patent US 20120328692
Sequence TAWYANXEKLXR
Sequence Length 12
UniProt ID Not available
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2
Chiral L
Physicochemical Information
Formula C57H82N16O14
Absent amino acids CDFGHIMPQSV
Common amino acids AX
Mass 163176
Pl 9.3
Basic residues 2
Acidic residues 1
Hydrophobic residues 4
Net charge 1
Boman Index -2576
Hydrophobicity -90.83
Aliphatic Index 49.17
Half Life
/
Extinction Coefficient cystines 6990
Absorbance 280nm 635.45
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2012/0328692 A1
Patent Title Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.
Other Iinformation Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status: Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.